骨质疏松女性首次静脉注射唑来膦酸或伊班膦酸后急性期反应的相关因素:未使用或曾使用双膦酸盐者
在瑞士伯尔尼大学医院骨质疏松科开展的前瞻性开放标签探索性研究,纳入725例连续绝经后骨质疏松女性,分别接受静脉唑来膦酸(411例)或伊班膦酸(314例)首次治疗。总体急性期反应发生率为41.5%,唑来膦酸组47.7%高于伊班膦酸组33.4%(p<0.001);既往双膦酸盐暴露可预测急性期反应风险和严重程度,较低的血清25-羟基维生素D水平可能预测严重程度。
要点
- 静脉双膦酸盐首次给药后急性期反应总体发生率为41.5%,唑来膦酸47.7% vs 伊班膦酸33.4%(p<0.001)。
- 未使用过双膦酸盐者中,唑来膦酸组急性期反应发生率55.6% vs 伊班膦酸组32.4%(p<0.001)。
- 急性期反应主要临床表现为给药后肌痛或关节痛(68.1%)。
核心结论
- 在真实临床环境中,唑来膦酸和伊班膦酸的急性期反应发生率可能高于随机对照试验报告,且可能因药物品种、既往双膦酸盐暴露和血清25-羟基维生素D水平而异。
- 既往双膦酸盐暴露可预测急性期反应风险和严重程度,较低的血清25-羟基维生素D水平可能预测严重程度。
研究设计与样本
- 开放标签前瞻性探索性研究,在瑞士伯尔尼大学医院骨质疏松科纳入两个连续绝经后骨质疏松女性队列,分别接受静脉唑来膦酸或伊班膦酸治疗。
- 共725例女性接受静脉双膦酸盐(唑来膦酸411例,伊班膦酸314例)。
主要发现
- 既往口服或静脉双膦酸盐使用在唑来膦酸组较少见(61.8% vs 71.7%,p=0.005)。
- 共301例女性(41.5%)报告至少一种急性期反应症状或体征,唑来膦酸组发生率为47.7%,伊班膦酸组为33.4%(p<0.001)。
- 在未使用过双膦酸盐的患者亚组中,唑来膦酸组急性期反应发生率为55.6%,伊班膦酸组为32.4%(p<0.001)。
- 急性期反应主要临床体征为给药后肌痛或关节痛(68.1%)。
- 既往双膦酸盐暴露可预测急性期反应风险和严重程度,较低的血清25-羟基维生素D水平可能预测严重程度。
关键数值与推荐
- 总体急性期反应发生率41.5%(301/725),唑来膦酸组47.7%,伊班膦酸组33.4%(p<0.001)。
- 未使用过双膦酸盐者中急性期反应发生率:唑来膦酸组55.6%,伊班膦酸组32.4%(p<0.001)。
- 既往口服或静脉双膦酸盐使用比例:唑来膦酸组61.8%,伊班膦酸组71.7%(p=0.005)。
- 肌痛或关节痛占急性期反应临床表现的68.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: A first intravenous dose of bisphosphonates may be associated with an acute-phase response (APR). In bisphosphonate-naïve women with postmenopausal osteoporosis, the characteristics and frequency of APR may differ by compound. Prior bisphosphonate exposure was predictive of APR risk and severity. INTRODUCTION: Intravenous (IV) administration of bisphosphonates (BP), such as zoledronate (ZOL) and ibandronate (IBN), may be associated with an APR. The characteristics of APR may differ by compound. The aim of the present study was to evaluate the characteristics of APR (rates, signs and symptoms, severity), in the absence of any preventive measure, after a first IV application of ZOL or IBN in patients naïve or previously exposed to BP in a real-world clinical setting. METHODS: This is an open-label prospective exploratory study with two cohorts of consecutive postmenopausal women with osteoporosis treated with either IV ZOL or IBN at the Department of Osteoporosis of the University Hospital of Berne, Switzerland. RESULTS: Intravenous BP was administered to 725 women (411 ZOL and 314 IBN). Prior oral or IV BP use was less frequent in the ZOL group (61.8 vs. 71.7%, p = 0.005). In total, 301 women (41.5%) reported the presence of one or more signs or symptoms of APR with rates for ZOL and IBN of 47.7 and 33.4%, respectively (p < 0.001). Corresponding APR rates in the subgroup of BP-naïve patients were 55.6 and 32.4%, respectively (p < 0.001). The leading APR clinical sign was the presence of post-dose myalgia or arthralgia (68.1%). Prior BP exposure was predictive of both APR risk and severity, and lower serum 25-hydroxy vitamin D (25(OH)D) levels were possibly predictive of severity. CONCLUSIONS: In a real-world setting, APR rates with ZOL and IBN may be higher than reported in randomised controlled trials and may differ by compound, prior BP exposure, and serum 25(OH)D levels.
引用
- Popp AW, Senn R, Curkovic I, et al. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos Int. 2017. PMID: 28299378. doi:10.1007/s00198-017-3992-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。